Voranigo®
vorasidenib tablets
40mg

FDA Approval of VORANIGO Marks First Major Cancer Breakthrough in Decades for *IDH*-Mutant Grade 2 Glioma

IDH-MUTANT GLIOMA IS A RELENTLESS FORM OF BRAIN CANCER

A glioma is a type of tumor that develops in the brain or spinal cord.[1] About 82 percent of all primary malignant brain tumors are gliomas.[2] Of those, at least 18 percent harbor what's known as an isocitrate dehydrogenase (*IDH*) mutation.[2]

IDH-mutant gliomas are malignant and incurable brain tumors that continue to grow and relentlessly infiltrate the brain, even after surgery.[3] Symptoms of glioma vary from patient to patient and can be affected by tumor type and location. Both before and after a glioma diagnosis, patients may experience a wide range of symptoms including changes in mental function, seizures, speech difficulties, new weakness or numbness in one or more body parts, headache, nausea and vomiting.[1] Approximately 2,400 patients a year in the U.S. are diagnosed with this aggressive cancer, but there are likely many more living on what physicians call a 'watch and wait,' or active surveillance, protocol.[3]

GLIOMA PATIENTS FACE SIGNIFICANT CHALLENGES AT A PIVOTAL TIME IN THEIR LIVES

A glioma diagnosis can be devastating. Patients with this condition are often young – in their 30s and 40s – and otherwise healthy.[4] They are generally in the prime of their lives, starting families, building their careers, and planning for their future.[4]

These patients experience complications to daily activities that have negative societal impact, with 65% being less productive at work, 46% needing 2 to 6 months of paid leave, and 13% needing 6 to 12 months of total paid time off.[5]

US-03346V1.0 09/24

PARTICIPANTS IN OUR PHASE III TRIAL, INDIGO, WERE REPRESENTATIVE OF THE REAL-WORLD *IDH*-MUTANT GLIOMA POPULATION.

- Nearly half of participants were between 18-40 years old; the other half were between 40-65 years old.
- 57% of participants were males, and around 3/4 of participants were White.

Patients with *IDH*-mutated gliomas may initially be asymptomatic or have unrecognized cognitive symptoms.[7] This allows the disease to progress further without treatment, potentially reducing survivability. Up to 77% of patients with *IDH*-mutated glioma had impairment in at least one area of mental function (e.g., decision- making, organization, language, memory).[7, 8]

VORANIGO OFFERS A TARGETED TREATMENT OPTION FOR PATIENTS

Servier has continued to push the boundaries of healthcare innovation with the approval of VORANIGO in *IDH*-mutated glioma, which adds to our footprint of products treating *IDH*-mutated cancer types that have high unmet need, including *IDH*-mutated acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma. VORANIGO was approved in the U.S. in August 2024 as an IDH1 and IDH2 inhibitor, indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible *IDH1* or *IDH2* mutation following surgery including biopsy, sub-total resection, or gross total resection. VORANIGO is available and offers glioma patients the ability to actively manage their disease with the convenience of a once-daily pill.

PATIENT OUTCOMES WITH VORANIGO

Results from INDIGO (NCT04164901), the pivotal clinical trial used for the FDA approval of VORANIGO, was the first major advance in low-grade *IDH*-mutated glioma. These positive results enabled data readout 18 months ahead of schedule, shortening the timeline to get this treatment to patients. Patients receiving VORANIGO during the trial:

- Survived nearly 17 months longer without disease progression[3]
- Had a 74% likelihood of not needing another treatment[3]
- 72% did not see disease progression compared to 46% on placebo[3]

SERVIER'S INNOVATION FOCUSES ON DEVELOPING TRANSFORMATIVE PRECISION THERAPIES FOR PATIENTS

Servier continues to choose the most innovative path forward, focusing on developing precision therapies for cancer care, and investing in areas where others have failed or considered it too risky. We have treated more than 30,000 patients in the U.S., guided by a passion for innovation and improving their lives and the lives of their families and caregivers.

We commit 20% of our profits to research and development, and more than 65% of that goes back into making groundbreaking advances for cancer types with significant unmet need and limited therapeutic options. When focused on serving patients, this is essential, considering that R&D is an inherently risky, costly, and time-consuming process. Due to these risks, other companies do not always have the flexibility to re-invest as large of a proportion of budget back into their R&D priority areas.

Overall development costs help set context here, which are estimated to cost $944M-4.5 billion USD to bring a drug to the marketplace in the U.S., with only 12% of all drugs entering clinical trials getting approved by FDA.[10, 11] Our commitment to develop treatments that serve patient

US-03346V1.0 09/24

needs in these hard-to-treat disease areas is integral to how we approach pricing our medicines, and how we are able to sustain high levels of re-investment into R&D to fuel future innovation and deliver more breakthrough treatments for patients eagerly seeking new therapeutic options.

We factor the outcomes that VORANIGO can offer patients with *IDH*-mutated glioma into our pricing approach for VORANIGO. Additionally, the continuous oral dosing regimen differentiates VORANIGO from existing treatment options.

Servier is a commercial stage, privately held pharmaceutical company, launched in the U.S. by Servier Group in 2018. With the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of a biotech, Servier has quickly become an oncology powerhouse built from the ground up.

Our unique operating model is governed by an independent non-profit foundation, which allows us to put patients before profits. This governance structure allows the Group to preserve its independence, guarantees a long-term vision and enables us to reinvest all our profits into a single priority: therapeutic progress to serve patient needs worldwide.

At Servier, we are deliberate in how we partner. We recognize the power of co-creation to help patients with *IDH*-mutant cancers that defy easy answers. There are many companies with technologies and approaches to treatment that complement our areas of research, and we believe that we often can do more together than we can alone.

SERVIER RELIES ON EVIDENCE TO ENSURE ACCESS

As an independent company, Servier has the ability to sustain high levels of re-investment from our brand medicine revenue back into our R&D focus areas and allows us to price our medicines in ways that consider our future innovation. It is our goal to ensure that the value of VORANIGO is fully aligned to its price and enables both broad coverage and patient affordability. Servier's approach to pricing VORANIGO was founded upon our principles of ensuring equitable access to innovative treatment options and balancing the reinvestment in R&D to continue development for hard-to-treat cancer types.

ACCESSING VORANIGO

Servier performs a comprehensive assessment of value in our approach to pricing medicines, which considers the ability for our treatments to re-define care options in cancer types with high unmet need, as well as their social and economic value. As part of this pricing approach, we are committed to ensuring our patients in the U.S. have access to our treatments, regardless of their financial or social circumstances. This includes individual support as well as opportunities to engage with other patients to help inform our approach so that it accurately reflects the needs and experiences of patients.

ServierONE™, our all- in-one personal support program for patient financial assistance. ServierONE can assist with determining insurance coverage, one-on-one support through care managers and access to educational tools.

Our **Patient Office** addresses patient journey challenges from the moment of diagnosis until long after their treatment ends.

Our **Patient Expert Council** contains contracted patients and their caregivers and provides insights back to us on meeting true patient needs.

US-03346V1.0 09/24

What is VORANIGO?

VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. Your healthcare provider will perform a test to make sure that VORANIGO is right for you. It is not known if VORANIGO is safe and effective in children under 12 years of age.

What are the possible side effects of VORANIGO?

VORANIGO may cause serious side effects, including:

- **Liver problems.** Changes in liver function blood tests may happen during treatment with VORANIGO and can be serious. Your healthcare provider will do blood tests to check your liver function before and during treatment with VORANIGO. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems:
  - yellowing of your skin or the white part of your eyes (jaundice)
  - dark tea-colored urine
  - loss of appetite
  - pain on the upper right side of your stomach area
  - feeling very tired or weak

The most common side effects of VORANIGO include:

- increased liver enzyme levels in the blood
- lack of energy, tiredness
- headache
- COVID-19
- muscle aches or stiffness
- diarrhea
- nausea
- seizure

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VORANIGO if you have certain side effects.

VORANIGO may affect fertility in females and males, which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of VORANIGO.

Before taking VORANIGO, tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems
- have kidney problems or are on dialysis
- smoke tobacco
- are pregnant or plan to become pregnant. VORANIGO can harm your unborn baby

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start treatment with VORANIGO
- You should use effective nonhormonal birth control during treatment with VORANIGO and for 3 months after the last dose. VORANIGO may affect how hormonal contraceptives (birth control) work and cause them to not work well. Talk to your healthcare provider about birth control methods that may be right for you during treatment with VORANIGO
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VORANIGO

Males with female partners who are able to become pregnant:

- You should use effective birth control during treatment with VORANIGO and for 3 months after the last dose
- Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant during your treatment with VORANIGO

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if VORANIGO passes into breast milk. **Do not** breastfeed during treatment with VORANIGO and for 2 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VORANIGO may affect the way other medicines work, and other medicines may affect how VORANIGO works.

Please see additional Important Safety Information and Full Prescribing Information.

US-03346V1.0 09/24

REFERENCES

1 Mayo Foundation for Medical Education and Research. “Glioma”. 2024. Accessed August 27, 2024. https://www.mayoclinic.org/diseases-conditions/glioma/symptoms-causes/syc-20350251

2 Ostrom Q, et al. *Neuro Oncol.* 2022;24 (suppl 5):v1-v95.

3 Mellinghoff I, et al. *N Engl J Med*. 2023;389(7):589-601

4 Molinaro A, et al. *Nat Rev. Biotech.* 2019;15: 405-417

5 Haider S, et al. *Neurology*. 2020;95(11):e1575-e1581.

6 Smits A, et al. *Neurosurg Clin North Am.* 2019;30(1):35-42

7 Van Kessel E, et al. *J Neuro Oncol.* 2017;134(1):9-18. 474

8 Wefel J, et al. *Neuro Oncol.* 2016;18(12):1656-1663

9 Wen P, et al. Presented at: Society for Neuro-Oncology 2023 Annual Meeting. Presentation #LTBK-06.

10 Schlander M, et al. *Pharmacoeconomics*. 2021; 39:1243-1269.

11 Heem Wong C, Wei Siah K S, Lo A. *Biostatistics*. 2019;20(2): 273–286